These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37799011)

  • 1. Agreement between one stage and chromogenic assays in samples from patients receiving recombinant porcine FVIII (Obizur, Susoctocog-alfa).
    Guy S; Bowyer AE; Shepherd MF; Maclean RM; Kitchen S
    Int J Lab Hematol; 2024 Feb; 46(1):135-140. PubMed ID: 37799011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories.
    Pipe S; Sadeghi-Khomami A; Konkle BA; Kitchen S; Negrier C; Liu M; Santagostino E; Willemze A; Abad-Franch L; Knobe K; Seth Chhabra E
    Haemophilia; 2024 Jan; 30(1):214-223. PubMed ID: 37902390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of different factor VIII replacement products using a factor VIII one-stage clotting assay on cobas t 511/711 analysers.
    Ketteler C; Hoffmann I; Davidson S; Tiede A; Richter N
    Haemophilia; 2021 Nov; 27(6):e704-e712. PubMed ID: 34590394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
    Bowyer A; Kitchen S; Maclean R
    Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analytical variation in factor VIII one-stage and chromogenic assays: Experiences from the ECAT external quality assessment programme.
    van Moort I; Meijer P; Priem-Visser D; van Gammeren AJ; Péquériaux NCV; Leebeek FWG; Cnossen MH; de Maat MPM
    Haemophilia; 2019 Jan; 25(1):162-169. PubMed ID: 30488994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analytical Performance of Different Laboratory Methods for Measuring Susoctocog-Alfa.
    Novembrino C; Quaglia I; Molinari AC; Borchiellini A; Coppola A; Santoro RC; Boscolo-Anzoletti M; Galbiati E; Zanon E; Valpreda A
    Diagnostics (Basel); 2022 Aug; 12(8):. PubMed ID: 36010349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: Data from the GTH-AH 01/2010 Study.
    Türkantoz H; Königs C; Knöbl P; Klamroth R; Holstein K; Huth-Kühne A; Heinz J; Eichler H; Tiede A
    J Thromb Haemost; 2020 Jan; 18(1):36-43. PubMed ID: 31448877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory coagulation tests and recombinant porcine factor VIII: A United Kingdom Haemophilia Centre Doctors' Organisation guideline.
    Bowyer A; Gray E; Lowe A; Murphy P; Platton S; Riddell A; Chowdary P; Lester W; Jenkins PV
    Haemophilia; 2022 May; 28(3):515-519. PubMed ID: 35279922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short term efficacy of recombinant porcine factor VIII in patients with factor VIII inhibitors.
    Abou-Ismail MY; Vuyyala S; Prunty J; Schmaier AH; Nayak L
    Haemophilia; 2020 Jul; 26(4):601-606. PubMed ID: 32338423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE.
    Turecek PL; Romeder-Finger S; Apostol C; Bauer A; Crocker-Buqué A; Burger DA; Schall R; Gritsch H
    Haemophilia; 2016 Nov; 22(6):957-965. PubMed ID: 27353010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A critical appraisal of one-stage and chromogenic assays of factor VIII activity.
    Peyvandi F; Oldenburg J; Friedman KD
    J Thromb Haemost; 2016 Feb; 14(2):248-61. PubMed ID: 26663865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII.
    Kitchen S; Jennings I; Makris M; Kitchen DP; Woods TA; Walker ID
    Haemophilia; 2016 Sep; 22(5):806-12. PubMed ID: 27217329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of extended half-life recombinant FVIII molecules:
    Lancellotti S; Sacco M; Tardugno M; Mancuso ME; De Cristofaro R
    Res Pract Thromb Haemost; 2023 Feb; 7(2):100070. PubMed ID: 36908765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A field study evaluating the activity of N8-GP in spiked plasma samples at clinical haemostasis laboratories.
    Tiefenbacher S; Clausen WHO; Hansen M; Lützhøft R; Ezban M
    Haemophilia; 2019 Sep; 25(5):893-901. PubMed ID: 31294905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of variation in reagent combinations for one-stage clotting assay on assay discrepancy in nonsevere haemophilia A.
    Suzuki A; Suzuki N; Kanematsu T; Okamoto S; Tamura S; Kikuchi R; Katsumi A; Kiyoi H; Kojima T; Matsushita T
    Int J Lab Hematol; 2021 Feb; 43(1):131-138. PubMed ID: 32915508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Factor VIII assays in treated hemophilia A patients].
    Lasne D; Pouplard C; Nougier C; Eschwege V; Le Cam Duchez V; Proulle V; Smahi M; Harzallah I; Voisin S; Toulon P; Sobas F; Galinat H; Flaujac C; Ternisien C; Jeanpierre E;
    Ann Biol Clin (Paris); 2019 Feb; 77(1):53-65. PubMed ID: 30799298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-reacting recombinant porcine FVIII inhibitors in patients with acquired haemophilia A.
    Bowyer A; Shepherd F; Platton S; Guy S; Kitchen S; Maclean R
    Haemophilia; 2020 Nov; 26(6):1181-1186. PubMed ID: 32997894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired haemophilia and haemostatic control with recombinant porcine factor VIII: case series.
    Campbell S; Mason J; Prasad R; Ambrose H; Hunt S; Tran H
    Intern Med J; 2021 Feb; 51(2):215-219. PubMed ID: 32043744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and laboratory monitoring of hemophilia A.
    Platton S; Sivapalaratnam S; Raheja P
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):11-18. PubMed ID: 38066923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of emicizumab and recombinant factor VIII in plasma: Which assays can we use for accurate measurement?
    Bowyer AE; Maclean RM; Kitchen S
    Int J Lab Hematol; 2023 Jun; 45(3):368-376. PubMed ID: 36710421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.